Kura, Kyowa Kirin Combo Data for KOMZIFTI (Ziftomenib) with Venetoclax and Azacitidine in AML

 – 86% (32/37) CRc and 73% (27/37) CR in newly diagnosed NPM1-m AML, with 68% (17/25) of CRc responders achieving molecular MRD negativity by central NGS 

– Median duration of complete response and overall survival not yet reached in newly diagnosed NPM1-m patients as of data cutoff –

– 65% (31/48) ORR in R/R NPM1-m AML, 83% (19/23) ORR in venetoclax-naïve –

– 41% (13/32) ORR in R/R KMT2A-r AML, 70% (7/10) ORR in venetoclax-naïve –

– Triplet combination was well tolerated in both newly diagnosed and relapsed/refractory settings; addition of ziftomenib did not increase toxicity beyond that expected with venetoclax/azacitidine alone –

– Ziftomenib’s broad clinical development program spans multiple front-line and relapsed/refractory regimens across NPM1-m, FLT3-m and KMT2A-r AML subtypes –

– Company-sponsored registrational trials of ziftomenib in front-line AML are ongoing in both intensive chemotherapy-eligible and -ineligible patients –

– Kura Oncology to host a virtual investor event today, December 8, 2025, at 12:30 p.m. ET / 9:30 a.m. PT –

Presentations
Slides from the oral presentations will be available on Kura’s website at www.kuraoncology.com under the Posters and Presentations tab in the Ziftomenib section, and in the ASH 2025 online program.

Virtual Investor Event
Kura will host a webcast and conference call today, December 8, 2025, at 12:30 p.m. ET / 9:30 a.m. PT featuring Kura management, Eunice Wang, M.D., Chief of Leukemia Service and Professor of Oncology at Roswell Park Comprehensive Center, and Amer Zeidan, M.B.B.S., M.H.S., Chief, Division of Hematologic Malignancies and Professor of Medicine at Yale School of Medicine. The live webcast and replay will be available on the on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.

https://www.globenewswire.com/news-release/2025/12/08/3201703/35186/en/Kura-Oncology-and-Kyowa-Kirin-Report-Combination-Data-for-KOMZIFTI-Ziftomenib-with-Venetoclax-and-Azacitidine-in-Newly-Diagnosed-and-Relapsed-Refractory-AML.html